BPC-157 FDA Approval Status 2026: Clinical Trials

BPC-157 FDA Approval Status 2026: Clinical Trials. Is BPC-157 FDA approved in 2026? See the latest compounding review, FDA docket updates, and what researchers need to know. Key Takeaways BPC-157 is NOT FDA approved. No finished-drug approval, no active IND, and no FDA-registered human clinical trials as of April 2026. RFK Jr February 2026 announcement: HHS Secretary Robert F. Kennedy Jr. publicly stated that 14 of 19 previously Category 2 peptides — including BPC-157 — would return to Category 1 compounding status. PCAC vote, July 23, 2026: The Pharmacy Compounding Advisory Committee voted 8-6 with one abstention to recommend BPC-157 free base and BPC-157 acetate for the FDA's 503A Bulks List, alongside KPV, TB-500, and MOTS-c. A recommendation is not an approval: The vote is non-binding. FDA must complete notice-and-comment rulemaking before BPC-157 is formally added to the 503A Bulks List, and a bulks-list listing is compounding eligibility only — never FDA drug approval. Reclassification ≠ FDA approval. A Category 1 listing only means a compound can be legally prepared by 503A compounding pharmacies — it does not make BPC-157 an FDA-approved drug. Research-grade BPC-157 remains available for laboratory and investigational use only, outside the compounding and therapeutic pathways entirely. The BPC-157 dosage calculator is a laboratory unit-conversion tool, not evidence of FDA approval or a clinically established dosing regimen. What Is BPC-157? BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide — 15 amino acids long — derived from a protective protein naturally found in human gastric juice. Researchers have studied its effects on tissue repair, angiogenesis, and nitric oxide signaling in preclinical models for more than two decades. The peptide is typically sold in two chemical forms used in compounding and research: BPC-157 free base (also called the pure peptide) and BPC-157 acetate , a trifluoroacetate-free salt form. The FDA's 2026 advisory committee review treats each form as a distinct evaluation target. Property Detail Full Name Body Protection Compound 157 Amino Acids 15 (pentadecapeptide) Sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val Molecular Weight ~1,419 g/mol Forms reviewed by FDA Free base and acetate salt FDA Status Not approved Active IND applications None (as of April 2026) Compounding status Recommended for the 503A Bulks List (8-6, July 23, 2026); FDA rulemaking pending Is BPC-157 FDA Approved in 2026? No. BPC-157 is not FDA approved. As of April 2026, the BPC-157 FDA approval status remains what it has been for the last two decades: no finished-drug approval, no active Investigational New Drug (IND) application, and no FDA-registered human clinical trials. The Drugs@FDA database contains no entry for BPC-157 in any indication, and ClinicalTrials.gov shows no ongoing human studies registered in the United States. That places BPC-157 in the same regulatory bucket as other unapproved research peptides like TB-500 (thymosin beta-4 fragment) and GHK-Cu . For the broader picture of which peptides ARE FDA approved, see our FDA Approved Peptides List 2026 . What has changed in 2026 is the compounding classification — the narrower regulatory question of whether 503A pharmacies can legally prepare BPC-157 prescriptions. That shift is driven by the RFK Jr announcement and the upcoming advisory committee meeting, covered below. The RFK Jr Announcement (February 27, 2026) On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. publicly stated during a Joe Rogan podcast appearance — and reiterated in follow-up HHS communications — that the FDA would return 14 of 19 previously Category 2 peptides to Category 1 compounding status . BPC-157 was among the 14 peptides named. The announcement was widely interpreted as a signal that the FDA under the new administration would take a more permissive stance toward peptide compounding than the 2023 Pharmacy Compounding Advisory Committee position, which had placed BPC-157 firmly in Category 2 (substances the FDA had concerns about for compounding use). What the Categories Actually Mean Category Meaning 503A Compounding? Category 1 Bulk substance the FDA considers eligible for use in compounding pending final rulemaking Generally permitted Category 2 Bulk substance the FDA has significant safety, identity, or quality concerns about Not permitted during review Category 3 Substance requiring further evaluation Case-by-case Critically, Category 1 status is not FDA approval. It simply permits licensed 503A compounding pharmacies to prepare the substance in response to individual prescriptions while the agency completes formal rulemaking. A Category 1 BPC-157 is still an unapproved drug — just one that compounders can legally dispense under specific conditions. July 23-24, 2026 Pharmacy Compounding Advisory Committee Meeting and Vote The RFK Jr announcement set up a formal review. On July 23-24, 2026 , the FDA's Pharmacy Compounding Advisory Committee (PCAC) convened at the FDA White Oak Campus (10903 New Hampshire Avenue, Silver Spring, MD 20993) to evaluate whether several peptides should be added to the Section 503A bulk drug substances list. The peptides specifically scheduled for review at the 2026 meeting include: BPC-157 free base BPC-157 acetate KPV (lysine-proline-valine tripeptide) TB-500 (thymosin beta-4 fragment) MOTS-c (mitochondrial-derived peptide) The committee voted on whether each listed substance met the statutory criteria under Section 503A(b)(1)(A)(i)(III) of the Federal Food, Drug, and Cosmetic Act for inclusion on the bulk drug substances list used in compounding. What the Committee Decided On July 23, 2026 , PCAC recommended the addition of BPC-157 free base and BPC-157 acetate — together with KPV, TB-500, and MOTS-c — to the 503A Bulks List. The BPC-157 votes were 8 in favor, 6 against, with 1 abstention . In a second session on July 24, 2026 , the committee also recommended Epitalon and Semax, and voted against adding Emideltide (also called DSIP) by a 6-7 margin with one abstention. The margins matter. The committee's discussion centered on how thin the human evidence base is for these compounds. FDA's briefing material for the meeting identified only a small number of human studies for BPC-157 — including a randomized placebo-controlled trial in ulcerative colitis reported as a 2005 meeting abstract (53 enrolled patients, rectal enema administration) — and no long-term human safety data. TB-500 fared worse on the same review: the briefing identified no human safety studies at all. Does the July 2026 PCAC Vote Mean BPC-157 Is Approved or Legal to Compound? Neither. Two separate steps still have to be completed before a compounded BPC-157 prescription is permitted under Section 503A: FDA rulemaking. An advisory committee recommendation is non-binding — the FDA has said it "generally follows" PCAC recommendations but is not legally bound to. FDA initiates notice-and-comment rulemaking and issues a final determination before a substance formally joins the 503A Bulks List. That process typically runs from several months to more than a year. A valid prescription and a licensed 503A pharmacy. Even once listed, compounding eligibility still depends on the individual patient, the prescriber, the pharmacy and state rules. What the recommendation does not do is approve BPC-157 as a drug. There is still no new drug application, no approved indication, no FDA-registered human clinical trial program for BPC-157, and no insurance coverage pathway. Any vendor or clinic presenting the July 2026 advisory vote as "FDA approval" is misreading what happened. Peptides Still Under Review The July 2026 session did not close the docket on peptides generally. PCAC has indicated it will further consider additions including injectable GHK-Cu , Melanotan II , Dihexa acetate , Cathelicidin LL-37 and PEG-MGF at a future meeting, so the 503A classification question continues to move into 2027. Public Docket FDA-2025-N-6895 The written-comment window on public docket FDA-2025-N-6895 closed on July 22, 2026 , the day before the meeting convened. The docket and the FDA's briefing documents remain part of the public record, and the notice-and-comment phase of formal rulemaking will open its own window. What Reclassification Would (and Would Not) Change The PCAC recommendation on its own changes nothing legally — the switch happens only if and when FDA completes rulemaking. When it does, the practical impact is narrower than many online summaries suggest: Scenario Category 2 (pre-vote default) 503A Bulks List (PCAC recommended) FDA approval No No 503A compounding Not permitted Permitted (pending final rulemaking) 503B outsourcing facilities Separate list (503B bulks list) Separate determination required Commercial drug product Not available Still not available without NDA Research/laboratory use Legal for research Legal for research (unchanged) In plain terms: Category 1 status lets a patient with a valid prescription get BPC-157 prepared by a state-licensed compounding pharmacy. It does not create a branded finished drug, it does not trigger insurance coverage, and it does not retroactively validate marketing claims made about the compound. Clinical Trial Landscape The BPC-157 clinical trials status is a critical piece of the 2026 picture. Despite more than 500 published preclinical studies (primarily animal and cell-culture models from Sikiric and colleagues at the University of Zagreb), there have been essentially no registered human clinical trials for BPC-157 in the United States. ClinicalTrials.gov searches return no active Phase 1, 2, or 3 trials. No pharmaceutical company has filed an IND application disclosed in the public record. This is the central regulatory problem that full FDA approval would need to solve — and it is the reason PCAC reviews for peptides like BPC-157 often hinge on available safety data rather than efficacy evidence from controlled human studies. BPC-157 vs Other Peptides Under Review The July 2026 advisory committee meeting is reviewing a cluster of peptides together. Here's how they compare: Peptide Primary research area FDA status Advisory committee review BPC-157 Tissue repair, angiogenesis Not approved Yes (free base + acetate) TB-500 Actin regulation, cell migration Not approved Yes MOTS-c Mitochondrial metabolism Not approved Yes KPV Anti-inflammatory Not approved Yes GHK-Cu Copper-peptide skin/healing Not approved Not on 2026 agenda For a deeper comparison of BPC-157 and its most-researched counterpart, see our BPC-157 vs TB-500 research comparison . Research-Grade BPC-157 vs Compounded BPC-157 There are two distinct supply channels for BPC-157, and the 2026 FDA activity only affects one of them: Research/laboratory grade: Sold by peptide research suppliers with third-party certificates of analysis (COA). Legal for laboratory and investigational use only. Not affected by the 503A compounding review. Not intended for human consumption. Compounded prescription: Prepared by a licensed 503A compounding pharmacy pursuant to a valid prescription from a licensed prescriber. This channel is the one directly affected by the Category 1/Category 2 decision. For researchers working in preclinical and laboratory contexts, the July 2026 decision does not change availability of research-grade material. It changes what happens downstream in the clinical compounding ecosystem. Frequently Asked Questions Is BPC-157 FDA approved in 2026? No. BPC-157 is not FDA approved for any therapeutic indication. The RFK Jr announcement and the July 23-24, 2026 Pharmacy Compounding Advisory Committee vote concern 503A compounding classification, not finished-drug approval. There are no active IND applications or FDA-registered human clinical trials for BPC-157, and the committee's favorable recommendation does not create any. What did RFK Jr announce about BPC-157? On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. publicly stated that 14 of 19 previously Category 2 peptides — BPC-157 among them — would return to Category 1 compounding status. That announcement precedes the formal July 2026 Pharmacy Compounding Advisory Committee vote but does not replace it. Final classification depends on the committee's recommendation and the FDA's subsequent rulemaking. When will the FDA decide on BPC-157 compounding status? The advisory committee phase is complete: PCAC met on July 23-24, 2026 and recommended BPC-157 (both free base and acetate forms), KPV, TB-500 and MOTS-c for the 503A Bulks List. What remains is FDA's own notice-and-comment rulemaking and final determination, which typically follows a committee vote by several months to more than a year. The earlier comment window on docket FDA-2025-N-6895 closed on July 22, 2026. Does Category 1 status mean BPC-157 is FDA approved? No. Category 1 status only means a substance is eligible for use by 503A compounding pharmacies pending final FDA rulemaking. It is not FDA approval as a finished drug product. BPC-157 would still require a full New Drug Application (NDA) supported by adequate human clinical trials to achieve formal FDA approval. What did the FDA advisory committee decide about BPC-157? On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee voted 8-6 with one abstention to recommend BPC-157 free base and BPC-157 acetate for the Section 503A Bulks List. The recommendation is advisory: FDA is not legally bound by it and must complete its own rulemaking before the listing takes effect. The same July 2026 session recommended KPV, TB-500 and MOTS-c, recommended Epitalon and Semax the following day, and declined to recommend Emideltide (DSIP). Does the July 2026 PCAC vote mean BPC-157 is approved? No. A 503A Bulks List recommendation is a compounding-eligibility step, not drug approval. BPC-157 still has no approved indication, no NDA, and no FDA-registered human clinical trials. Even after formal listing, compounded BPC-157 would require a valid prescription prepared by a licensed 503A pharmacy, and research-grade material would remain outside that channel entirely. What is the BPC-157 TB-500 FDA approval status 2026? Both remain unapproved. The BPC-157 TB-500 FDA approval status 2026 is identical at the approval level — neither compound has FDA approval, active INDs, or registered human clinical trials. Both were recommended by PCAC on July 23, 2026 for the 503A Bulks List (8-6 with one abstention each), which is a separate regulatory question from approval and still requires FDA rulemaking. For the parallel review of TB-500 specifically, see our TB-500 FDA approval status 2026 breakdown. Can I legally buy BPC-157 in 2026? Research-grade BPC-157 is legal to purchase for laboratory and investigational research in the United States. It is not a DEA-scheduled controlled substance. It is not legal to sell as a dietary supplement, and it is not approved for human consumption. Compounded BPC-157 from a 503A pharmacy requires a valid prescription from a licensed prescriber and depends on the compounding classification outcome. Is BPC-157 banned by WADA? As of April 2026, BPC-157 is not explicitly listed on the World Anti-Doping Agency (WADA) Prohibited List by name, though WADA's catch-all S0 category (non-approved substances) captures any compound without regulatory approval for human therapeutic use. This contrasts with TB-500, which is explicitly WADA-prohibited under S2. Conclusion The BPC-157 FDA approval status 2026 is unambiguous at the approval level: BPC-157 is not FDA approved, has no active IND, and has no registered human clinical trials. What changed in 2026 is the compounding classification question — driven by the February 27, 2026 RFK Jr announcement and moved forward when the Pharmacy Compounding Advisory Committee voted 8-6 (one abstention) on July 23, 2026 to recommend BPC-157's addition to the 503A Bulks List. If FDA adopts that recommendation after rulemaking, BPC-157 could become eligible for preparation by 503A compounding pharmacies against valid prescriptions. That is a meaningful shift for the clinical compounding ecosystem — but it is not the same as FDA approval of a finished drug product, and it is not yet in effect. For researchers, the laboratory-grade supply channel remains unchanged. For a direct comparison with the parallel peptide under review, see our TB-500 FDA approval status 2026 article. For the broader picture of which peptides already have FDA approval, see our FDA Approved Peptides List 2026 . Compounds under review alongside BPC-157 — including KPV and TB-500 — are profiled in our list of anti-inflammatory peptides . Reconstitution math: Use our free Peptide Calculator to determine concentration, syringe units, and doses per vial for your research protocols. References U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. fda.gov Liang L. Peptides: US advisory committee recommends six for FDA "compounding list". BMJ . 2026;394:e100422. bmj.com Fu M, Ross JS, Nguyen N-TA, Ramachandran R. FDA Advisory Committee's Vote May Open A Drug-Compounding Back Door For Unapproved Peptides. Health Affairs Forefront . August 4, 2026. healthaffairs.org U.S. Food and Drug Administration. FDA-2025-N-6895 Public Docket — 503A Compounding Bulk Drug Substances List Nominations (comments due July 22, 2026). regulations.gov U.S. Food and Drug Administration. Human Drug Compounding — Section 503A of the FD&C Act. fda.gov Sikiric P, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des . 2011;17(16):1612-32. PubMed Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol . 2011;110(3):774-80. PubMed Seiwerth S, et al. BPC 157 and Standard Angiogenic Growth Factors. Curr Pharm Des . 2018;24(18):1972-1989. PubMed Drugs@FDA Database — search for "BPC-157" (returns no results confirming unapproved status). accessdata.fda.gov ClinicalTrials.gov. BPC-157 clinical trial registry search (no active US Phase 1-3 trials). clinicaltrials.gov Related reading: Every peptide FDA status guide in one place — the peptide FDA status & legality hub . PeptideStack page context: visitors can use the header navigation to reach the product catalog, blog, calculators, supplier pages, discount-code pages, contact page, legal policies, privacy policy, terms, and research disclaimer. The site is organized around research peptide education, supplier transparency, product comparison, vendor review content, discount-code tracking, and calculator tools for reconstitution or unit conversion research planning. PeptideStack separates research-use-only peptide information from FDA-approved medication and licensed telehealth pathways. Research peptide pages are informational and are not medical advice, prescription guidance, dosing instructions, treatment recommendations, or instructions for human consumption. Many pages include affiliate disclosures because PeptideStack may earn a commission when visitors click external supplier or telehealth links. That commission does not change the price paid by visitors and does not mean PeptideStack manufactures, sells, distributes, compounds, or ships peptides or medications. Supplier and product pages should be evaluated for third-party testing, batch-specific certificates of analysis, named laboratory verification, transparent pricing, realistic delivery expectations, payment security, refund policies, support quality, and consistent research-use-only labeling. Blog pages connect related guides, comparison articles, FDA approval status explainers, safety context, legality resources, product pages, vendor reviews, and calculator tools so visitors can keep researching without relying on a single supplier claim. Calculator pages are educational tools for laboratory planning and should be cross-checked against professional protocols, institutional requirements, and applicable laws. Legal and disclaimer pages explain the boundaries of PeptideStack content and the responsibility of visitors who evaluate third-party vendors. The rendered interface may add interactive details such as mobile navigation labels, product tabs, share buttons, related article cards, disclosure boxes, call-to-action buttons, vendor selectors, copy-code controls, email-code forms, footer navigation, and status labels. The static HTML fallback includes this context so the same page purpose is understandable before the JavaScript application finishes loading. Visitors should treat PeptideStack as a research and comparison starting point. Final supplier evaluation should include direct review of the external vendor website, current product availability, checkout terms, applicable laws, institutional requirements, and any third-party laboratory documentation available for the exact product or batch being considered. Footer resources repeat important sitewide context: PeptideStack is independent, affiliate-supported, research-focused, and not a pharmacy or manufacturer. Pages may include links to the iOS app, calculators, blog hubs, product hubs, supplier comparisons, support contact, and policy documents. This repeated context is intentionally available in the raw HTML for crawlers that inspect a page before executing the React bundle. Raw HTML also includes page summaries for mobile crawlers using JavaScript rendering, desktop crawlers comparing source to rendered output, accessibility tools, and no-script visitors. The fallback is replaced by the React app in normal browsers but keeps the source document aligned with the visible page topic. This fallback keeps source HTML and rendered HTML closer for crawl diagnostics and SEO audits across crawled pages, routes, reports, and recrawls.